Literature DB >> 10344109

Functional prognosis after treatment of spinal dural arteriovenous fistulas.

S Ushikoshi1, K Hida, Y Kikuchi, K Miyasaka, T Iwasaki, H Abe.   

Abstract

Functional prognosis after treatment for spinal dural arteriovenous fistulas (SDAVFs) was retrospectively analyzed in 13 consecutive patients aged 38 to 73 years (mean 57 years) treated during the last 5 years. The duration of symptoms before diagnosis ranged from 3 to 72 months (mean 23 months). Neurological symptoms were examined before and 6 months after the treatment. Seven patients underwent embolization as the initial treatment. In four of six patients, N-butyl 2-cyanoacrylate (NBCA) embolization achieved complete obliteration of SDAVF. The other two patients with incomplete embolization and one embolized with polyvinyl alcohol particles underwent subsequent surgical treatment. Six patients were treated by direct surgery. Complete disappearance of SDAVF was confirmed in all nine patients treated surgically. Improvement of gait and micturition disturbance after the treatment was noted in six of 10 and three of six patients, respectively. Long duration of symptoms and high grade of neurological symptoms were associated with a poor functional outcome. NBCA embolization and surgery are curative treatments for SDAVF, but the functional prognosis is not always satisfactory. Embolization is the first choice of treatment for SDAVF because it is less invasive and relatively safe. However, when complete obliteration is not achieved, prompt surgery is recommended because a long duration of symptoms will result in a poor functional prognosis.

Entities:  

Mesh:

Year:  1999        PMID: 10344109     DOI: 10.2176/nmc.39.206

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  7 in total

1.  Single center experience with treatment of spinal dural arteriovenous fistulas.

Authors:  Neriman Özkan; Ilonka Kreitschmann-Andermahr; Sophia Luise Goerike; Karsten Henning Wrede; Bernadette Kleist; Klaus-Peter Stein; Oliver Gembruch; Ibrahim Erol Sandalcioglu; Isabel Wanke; Ulrich Sure
Journal:  Neurosurg Rev       Date:  2015-07-17       Impact factor: 3.042

2.  N-butyl 2-cyanoacrylate embolization of spinal dural arteriovenous fistulae.

Authors:  J K Song; Y P Gobin; G R Duckwiler; Y Murayama; J G Frazee; N A Martin; F Viñuela
Journal:  AJNR Am J Neuroradiol       Date:  2001-01       Impact factor: 3.825

3.  Treatment of intramedullary arteriovenous malformations of the spinal cord.

Authors:  S Ushikoshi; K Hida; Y Kikuchi; Y Iwasaki; K Miyasaka; H Abe
Journal:  Interv Neuroradiol       Date:  2001-05-15       Impact factor: 1.610

4.  Acute neurological deterioration after surgical interruption of spinal dural arteriovenous fistulas: clinical characteristics, possible predictors, and treatment. Patient series.

Authors:  Akihiko Saito; Naoki Yajima; Kimihiko Nakamura; Yukihiko Fujii
Journal:  J Neurosurg Case Lessons       Date:  2021-12-20

5.  [Clinical outcomes following microsurgery and endovascular embolization in the management of spinal dural arteriovenous fistula: A meta-analysis study].

Authors:  C W Yuan; Y J Wang; S J Zhang; S L Shen; H Z Duan
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-04-18

6.  Endovascular and surgical treatment of spinal dural arteriovenous fistulas.

Authors:  Robert H Andres; Alain Barth; Raphael Guzman; Luca Remonda; Marwan El-Koussy; Rolf W Seiler; Hans R Widmer; Gerhard Schroth
Journal:  Neuroradiology       Date:  2008-06-28       Impact factor: 2.804

7.  Perfusion-weighted MRI of spinal dural arteriovenous fistula.

Authors:  K Yanaka; Y Matsumaru; K Uemura; A Matsumura; I Anno; T Nose
Journal:  Neuroradiology       Date:  2003-09-06       Impact factor: 2.804

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.